No Data
No Data
GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections
GSK Says Health Canada Approves Jemperli as Endometrial Cancer Treatment
GlaxoSmithKline (GSK) Receives a Buy From Jefferies
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
ViiV Healthcare Announces Positive Data Demonstrating 2-drug Regimen Dovato Is as Effective as 3-drug Regimen Biktarvy for Maintenance Therapy of HIV-1